Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project

Lindsay M. Morton(National Institutes of Health), Susan L Slager(Mayo Clinic), James R. Cerhan(Mayo Clinic), Sophia Wang(City Of Hope National Medical Center), Claire M. Vajdic(UNSW Sydney), Christine F. Skibola(University of Alabama at Birmingham), Paige M. Bracci(University of California, San Francisco), Silvia de Sanjosé(National Institutes of Health), Karin E. Smedby(Karolinska Institutet), Brian C.‐H. Chiu(University of Chicago), Yawei Zhang(Yale University), Sam M. Mbulaiteye(National Institutes of Health), Alain Monnereau(Université de Bordeaux), Jennifer Turner(Department of Health and Human Services), Jacqueline Clavel(Université Paris-Sud), Hans‐Olov Adami(Harvard University Press), Ellen T. Chang(Exponent (United States)), Bengt Glimelius(Uppsala University), Henrik Hjalgrim(Statens Serum Institut), Mads Melbye(Statens Serum Institut), Paolo Crosignani(National Institutes of Health), Simonetta Di Lollo(Department of Health and Human Services), Lucia Miligi(National Institutes of Health), Oriana Nanni(National Institutes of Health), Valerio Ramazzotti(National Institutes of Health), Stefania Rodella(National Institutes of Health), Adele Seniori Costantini(National Institutes of Health), Emanuele Stagnaro(National Institutes of Health), ­Rosario ­Tumino(National Institutes of Health), Carla Vindigni(National Institutes of Health), Paolo Vineis(Department of Health and Human Services), Nikolaus Becker(German Cancer Research Center), Yolanda Benavente(National Institutes of Health), Paolo Boffetta(Department of Health and Human Services), Paul Brennan(Department of Health and Human Services), Pierluigi Cocco(University of Cagliari), Lenka Foretová(National Institutes of Health), Marc Maynadié(Université de Bourgogne), Alexandra Nieters(University of Freiburg), Anthony Staines(Department of Health and Human Services), Joanne S. Colt(National Institutes of Health), Wendy Cozen(University of Southern California), Scott Davis(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Anneclaire J. De Roos(Department of Health and Human Services), Patricia Hartge(National Institutes of Health), N. Rothman(National Institutes of Health), Richard K. Severson(Wayne State University), Elizabeth A. Holly(University of California, San Francisco), Timothy G. Call(Mayo Clinic), Andrew L. Feldman(Mayo Clinic), Thomas M. Habermann(Mayo Clinic), Mark Liebow(Mayo Clinic), A Blair(National Institutes of Health), Kenneth P. Cantor(National Institutes of Health), Eleanor Kane(Department of Health and Human Services), Tracy Lightfoot(Department of Health and Human Services), Eve Roman(Department of Health and Human Services), Alex Smith(Department of Health and Human Services), Angela Brooks‐Wilson(University of British Columbia), Joseph M. Connors(University of British Columbia), Randy D. Gascoyne(University of British Columbia), John J. Spinelli(University of British Columbia), Bruce K. Armstrong(The University of Sydney), Anne Kricker(The University of Sydney), Theodore R. Holford(Yale University), Qing Lan(National Institutes of Health), Tongzhang Zheng(Yale University), Laurent Orsi(Université Paris-Sud), Luigino Dal Maso(National Institutes of Health), Silvia Franceschi(Department of Health and Human Services), Carlo La Vecchia(University of Milan), Eva Negri(Mario Negri Institute for Pharmacological Research), Diego Serraino(National Institutes of Health), Leslie Bernstein(City Of Hope National Medical Center), Alexandra M. Levine(City Of Hope National Medical Center), Jonathan W. Friedberg(Department of Health and Human Services), Jennifer L. Kelly(Department of Health and Human Services), Sonja I. Berndt(National Institutes of Health), Brenda M. Birmann(Harvard University Press), Christina A. Clarke(Cancer Prevention Institute of California), Christopher R. Flowers(Emory University), James M. Foran(Mayo Clinic), Marshall E. Kadin(Boston University), Ora Paltiel(National Institutes of Health), Dennis D. Weisenburger(City Of Hope National Medical Center), Martha S. Linet(National Institutes of Health), Joshua N. Sampson(National Institutes of Health)
JNCI Monographs
August 1, 2014
Cited by 334Open Access
Full Text

Abstract

BACKGROUND: Non-Hodgkin lymphoma (NHL) comprises biologically and clinically heterogeneous subtypes. Previously, study size has limited the ability to compare and contrast the risk factor profiles among these heterogeneous subtypes. METHODS: We pooled individual-level data from 17 471 NHL cases and 23 096 controls in 20 case-control studies from the International Lymphoma Epidemiology Consortium (InterLymph). We estimated the associations, measured as odds ratios, between each of 11 NHL subtypes and self-reported medical history, family history of hematologic malignancy, lifestyle factors, and occupation. We then assessed the heterogeneity of associations by evaluating the variability (Q value) of the estimated odds ratios for a given exposure among subtypes. Finally, we organized the subtypes into a hierarchical tree to identify groups that had similar risk factor profiles. Statistical significance of tree partitions was estimated by permutation-based P values (P NODE). RESULTS: Risks differed statistically significantly among NHL subtypes for medical history factors (autoimmune diseases, hepatitis C virus seropositivity, eczema, and blood transfusion), family history of leukemia and multiple myeloma, alcohol consumption, cigarette smoking, and certain occupations, whereas generally homogeneous risks among subtypes were observed for family history of NHL, recreational sun exposure, hay fever, allergy, and socioeconomic status. Overall, the greatest difference in risk factors occurred between T-cell and B-cell lymphomas (P NODE < 1.0×10(-4)), with increased risks generally restricted to T-cell lymphomas for eczema, T-cell-activating autoimmune diseases, family history of multiple myeloma, and occupation as a painter. We further observed substantial heterogeneity among B-cell lymphomas (P NODE < 1.0×10(-4)). Increased risks for B-cell-activating autoimmune disease and hepatitis C virus seropositivity and decreased risks for alcohol consumption and occupation as a teacher generally were restricted to marginal zone lymphoma, Burkitt/Burkitt-like lymphoma/leukemia, diffuse large B-cell lymphoma, and/or lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. CONCLUSIONS: Using a novel approach to investigate etiologic heterogeneity among NHL subtypes, we identified risk factors that were common among subtypes as well as risk factors that appeared to be distinct among individual or a few subtypes, suggesting both subtype-specific and shared underlying mechanisms. Further research is needed to test putative mechanisms, investigate other risk factors (eg, other infections, environmental exposures, and diet), and evaluate potential joint effects with genetic susceptibility.


Related Papers

No related papers found

Powered by citation graph analysis